Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anemia induced by solid tumor chemotherapy].

Roberto Stasi1, Luca Abriani, Patrizia Beccaglia

  • 1Dipartimento di Scienze Mediche, Ospedale Regina Apostolorum, Albano Laziale. roberto.stasi@libero.it

Recenti Progressi in Medicina
|December 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Blood advances·2026
Same author

<i>Erratum</i> to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".

Haematologica·2026
Same author

Retraction Note: Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) induce apoptosis in K562 cells.

BMC cancer·2025
Same author

FLT3-ITD measurable residual disease from the QuANTUM-First trial.

Blood advances·2025
Same author

Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial.

Haematologica·2025
Same author

Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.

American journal of hematology·2024

Chemotherapy often causes anemia, impacting cancer patients' quality of life. New research suggests focusing on hemoglobin levels and patient well-being may refine anemia treatment strategies.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Research

Context:

  • Anemia is a common chemotherapy complication affecting cancer patients.
  • Recent research highlights the link between anemia, fatigue, and quality of life (QOL).
  • Mild-to-moderate anemia significantly reduces patient energy levels and QOL.

Purpose:

  • To review the incidence and severity of anemia in non-hematologic malignancies treated with chemotherapy.
  • To explore the impact of anemia on patient well-being and QOL.
  • To inform new therapeutic strategies for chemotherapy-induced anemia.

Summary:

  • Chemotherapy regimens for major non-hematologic malignancies frequently lead to mild-to-moderate anemia.
  • Despite reporting flaws, data indicate a high incidence of treatment-related anemia.

Related Experiment Videos

  • Recombinant human erythropoietin is now available for anemia treatment.

    • Impact:

    • Emerging research may lead to a new classification of chemotherapy-induced anemia.
    • Increased emphasis on QOL may challenge the notion of enduring lesser degrees of anemia.
    • Further understanding of hemoglobin levels and patient well-being can refine anemia management.